SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103)

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 644-649

  Raeppel, Stéphane ^a   Zhou, Nancy ^a   Gaudette, Frédéric ^a   Leit, Silvana ^a   Paquin, Isabelle ^a   Larouche, Guillaume ^a   Moradei, Oscar ^a   Fréchette, Sylvie ^a   Isakovic, Ljubomir ^a   Delorme, Daniel ^a   Fournel, Marielle ^a   Kalita, Ann ^a   Lu, Aihua ^a   Trachy Bourget, Marie Claude ^a   Yan, Pu Theresa ^a   Liu, Jianhong ^a   Rahil, Jubrail ^a   Wang, James ^a   Besterman, Jeffrey M ^a   Murakami, Koji ^b   Li, Zuomei ^a   Vaisburg, Arkadii ^a   more..

^a METHYLGENE INC   (Canada)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Class I; HDAC; Inhibitors; MGCD0103; Oncology

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASM TRANSPLANTATION; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58549105898     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.12.048     Document Type: Article

References (16)

1. For a review see. Glozak M., and Seto E. Oncogene 26 (2007) 5420
2. For a review see. Yang X.-J. Nat. Rev. Mol. Cell Biol. 9 (2008) 207
3. For recent reviews see. ten Holte P., Van Emelen K., Janicot M., Fong P.C., de Bono J.S., and Arts J. Top. Med. Chem. 1 (2007) 293
4. Paris M., Porcelloni M., Binaschi M., and Fattori D. J. Med. Chem. 51 (2008) 1505
5. Moradei O., Vaisburg A., and Martell R.E. Curr. Top. Med. Chem. 8 (2008) 841
6. Zhou N.Z., Moradei O., Raeppel S., Leit S., Fréchette S., Gaudette F., Paquin I., Bernstein N., Bouchain G., Vaisburg A., Jin Z., Gillespie J., Wang J.J., Fournel M., Yan P.T., Trachy-Bourget M.-C., Kalita A., Lu A.-H., Rahil J., MacLeod A.R., Li Z., Besterman J.M., and Delorme D. J. Med. Chem. 51 (2008) 4072
7. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.-C., Kalita A., Liu J., Lu A.-H., Zhou N.Z., Robert M.-F., Gillespie J., Wang J.J., Ste-Croix H., Rahil J., Lefebvre S., Moradei O., Delorme D., MacLeod A.R., Besterman J.M., and Li Z. Mol. Cancer Ther. 7 4 (2008) 759
8. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., Tumber A., Ritchie J.W., Jensen P.B., Lichenstein H.S., and Sehested M. Biochem. J. 409 (2008) 581
9. Kell J. Curr. Opin. Investig. Drugs 8 (2007) 478
10. Bonfils C., Walkinshaw D.R., Besterman J.M., Yang X.-J., and Li Z. Expert Opin. Drug Discov. 3 (2008) 1041
11. The details for the synthesis and the characterization of all the new compounds are described in PCT WO 2003/024448 A2, WO 2004/035525 A1, and WO 2005/092899 A1. All compounds were initially screened for their ability to inhibit recombinant human HDAC1. We targeted this isotype following the results of our work and of others which implicated HDAC1 for both transcriptional repression and chromatin remodeling (Carmen, A. A.; Rundlett, S. E.; Grunstein, M. J. Biol. Chem. 1996, 271, 15837). The compounds were screened as described earlier, using Boc_Lys(acetyl)-AMC as substrate. The in vitro anti-proliferative activities of the synthesized compounds against HCT116 human colon cancer cell line were evaluated using 3-[4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT).
12. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., and Nakanishi O. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4592
13. Suzuki T., Ando T., Tsuchiya K., Fukasawa N., Saito A., Mariko Y., Yamashita T., and Nakanishi O. J. Med. Chem. 42 (1999) 3001
14. US Patent 6174905, 2001.
15. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., and Sausville E.A. J. Clin. Oncol. 23 (2005) 3912
16. Paquin I., Raeppel S., Leit S., Gaudette F., Zhou N., Moradei O., Saavedra O., Bernstein N., Raeppel F., Bouchain G., Fréchette S., Woo S.H., Vaisburg A., Fournel M., Kalita A., Robert M.-F., Lu A.-H., Trachy-Bourget M.-C., Yan P.T., Liu J., Rahil J., MacLeod A.R., Besterman J.M., Li Z., and Delorme D. Bioorg. Med. Chem. Lett. 18 (2008) 1067